المؤلفون: Geurts SME; Department of Medical Oncology, GROW- School for Oncology and Reproduction, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands. sandra.geurts@mumc.nl., Ibragimova KIE; Department of Medical Oncology, GROW- School for Oncology and Reproduction, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands., Ding N; Department of Medical Oncology, GROW- School for Oncology and Reproduction, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands., Meegdes M; Department of Medical Oncology, GROW- School for Oncology and Reproduction, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands., Erdkamp F; Department of Internal Medicine, Zuyderland Medical Center, Sittard-Geleen, The Netherlands., Heijns JB; Department of Medical Oncology, Amphia, Breda, The Netherlands., Tol J; Department of Medical Oncology, Jeroen Bosch Hospital, Den Bosch, The Netherlands., Vriens BEPJ; Department of Internal Medicine, Catharina Hospital, Eindhoven, The Netherlands., Dercksen MW; Department of Medical Oncology, Máxima Medical Center, Eindhoven, The Netherlands., Aaldering KNA; Department of Internal Medicine, Laurentius Hospital, Roermond, The Netherlands., Pepels MJAE; Department of Internal Medicine, Elkerliek Hospital, Helmond, The Netherlands., van de Winkel L; Department of Internal Medicine, St Anna Hospital, Geldrop, The Netherlands., Peters NAJB; Department of Internal Medicine, Sint Jans Gasthuis Hospital, Weert, Netherlands., van de Wouw AJ; Department of Internal Medicine, Viecuri Medical Centre, Venlo, The Netherlands., Maaskant SAJG; Department of Surgery, Máxima Medical Center, Eindhoven, The Netherlands., Teeuwen-Dedroog NJA; Department of Medical Oncology, GROW- School for Oncology and Reproduction, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands., van Nijnatten TJA; Department of Radiology and Nuclear Medicine, GROW, Maastricht University Medical Center, Maastricht, The Netherlands., de Boer M; Department of Medical Oncology, GROW- School for Oncology and Reproduction, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands., Tjan-Heijnen VCG; Department of Medical Oncology, GROW- School for Oncology and Reproduction, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands.

المصدر: Breast cancer research and treatment [Breast Cancer Res Treat] 2024 Jun; Vol. 205 (2), pp. 287-302. Date of Electronic Publication: 2024 Feb 21.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/mortality , Breast Neoplasms*/pathology , Breast Neoplasms*/therapy , Receptor, ErbB-2*/metabolism , Registries*, Humans ; Female ; Middle Aged ; Aged ; Adult ; Aged, 80 and over ; Neoplasm Metastasis ; Kaplan-Meier Estimate ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use

المؤلفون: Ibragimova KIE; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands; GROW-School for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands., Geurts SME; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands; GROW-School for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands., Laczkó D; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands., Meegdes M; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands; GROW-School for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands., Erdkamp F; Department of Internal Medicine, Zuyderland Medical Center, Sittard-Geleen, The Netherlands., Heijns JB; Department of Medical Oncology, Amphia, Breda, The Netherlands., Tol J; Department of Medical Oncology, Jeroen Bosch Hospital, Den Bosch, The Netherlands., Vriens BEPJ; Department of Internal Medicine, Catharina hospital, Eindhoven, The Netherlands., Aaldering KNA; Department of Internal Medicine, Laurentius hospital, Roermond, The Netherlands., Dercksen MW; Department of Medical Oncology, Máxima Medical Center, Eindhoven, The Netherlands., Pepels MJAE; Department of Internal Medicine, Elkerliek hospital, Helmond, The Netherlands., Peters NAJB; Department of Internal Medicine, St. Jans Gasthuis, Weert, The Netherlands., van de Winkel LMH; Department of Internal Medicine, St Anna Hospital, Geldrop, The Netherlands., van de Wouw AJ; Department of Internal Medicine, Viecuri Medical Centre, Venlo, The Netherlands., de Fallois A; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands., van Kats MACE; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands; GROW-School for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands., Tjan-Heijnen VCG; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands; GROW-School for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands. Electronic address: vcg.tjan.heijnen@mumc.nl.

المصدر: Clinical breast cancer [Clin Breast Cancer] 2024 Feb; Vol. 24 (2), pp. 103-111. Date of Electronic Publication: 2023 Nov 02.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 100898731 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0666 (Electronic) Linking ISSN: 15268209 NLM ISO Abbreviation: Clin Breast Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/pathology, Humans ; Female ; Trastuzumab ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Receptor, ErbB-2/metabolism ; Progression-Free Survival ; Proportional Hazards Models

المؤلفون: Lammers SWM; Department of Medical Oncology, Maastricht University Medical Centre, GROW, Maastricht University, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands., Thurisch H; Department of Medical Oncology, Maastricht University Medical Centre, GROW, Maastricht University, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands., Vriens IJH; Department of Medical Oncology, Maastricht University Medical Centre, GROW, Maastricht University, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands., Meegdes M; Department of Medical Oncology, Maastricht University Medical Centre, GROW, Maastricht University, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands., Engelen SME; Department of Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands., Erdkamp FLG; Department of Internal Medicine, Zuyderland Medical Centre, Sittard-Geleen, The Netherlands., Dercksen MW; Department of Medical Oncology, Máxima Medical Centre, Eindhoven, The Netherlands., Vriens BEPJ; Department of Internal Medicine, Catharina Hospital, Eindhoven, The Netherlands., Aaldering KNA; Department of Internal Medicine, Laurentius Hospital, Roermond, The Netherlands., Pepels MJAE; Department of Internal Medicine, Elkerliek Hospital, Helmond, The Netherlands., van de Winkel LMH; Department of Internal Medicine, St. Anna Hospital, Geldrop, The Netherlands., Peters NAJB; Department of Internal Medicine, St. Jans Gasthuis, Weert, The Netherlands., Tol J; Department of Internal Medicine, Jeroen Bosch Hospital, Den Bosch, The Netherlands., Heijns JB; Department of Internal Medicine, Amphia Hospital, Breda, The Netherlands., van de Wouw AJ; Department of Internal Medicine, Viecuri Medical Centre, Venlo, The Netherlands., Teeuwen NJA; Department of Medical Oncology, Maastricht University Medical Centre, GROW, Maastricht University, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands., Geurts SME; Department of Medical Oncology, Maastricht University Medical Centre, GROW, Maastricht University, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands., Tjan-Heijnen VCG; Department of Medical Oncology, Maastricht University Medical Centre, GROW, Maastricht University, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands. vcg.tjan.heijnen@mumc.nl.

المصدر: Breast cancer research and treatment [Breast Cancer Res Treat] 2024 Jan; Vol. 203 (2), pp. 339-349. Date of Electronic Publication: 2023 Oct 25.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/complications , Breast Neoplasms*/epidemiology , Breast Neoplasms*/metabolism, Humans ; Female ; Prognosis ; Overweight/complications ; Overweight/epidemiology ; Body Mass Index ; Thinness/complications ; Obesity/complications ; Obesity/epidemiology

المؤلفون: Ibragimova KIE; Department of Medical Oncology, GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, PO BOX 5800, 6202 AZ, Maastricht, the Netherlands., Geurts SME; Department of Medical Oncology, GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, PO BOX 5800, 6202 AZ, Maastricht, the Netherlands., Meegdes M; Department of Medical Oncology, GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, PO BOX 5800, 6202 AZ, Maastricht, the Netherlands., Erdkamp F; Department of Internal Medicine, Zuyderland Medical Center, Sittard-Geleen, the Netherlands., Heijns JB; Department of Medical Oncology, Amphia, Breda, the Netherlands., Tol J; Department of Medical Oncology, Jeroen Bosch Hospital, Den Bosch, the Netherlands., Vriens BEPJ; Department of Internal Medicine, Catharina Hospital, Eindhoven, the Netherlands., Dercksen MW; Department of Medical Oncology, Máxima Medical Center, Eindhoven, the Netherlands., Aaldering KNA; Department of Internal Medicine, Laurentius Hospital, Roermond, the Netherlands., Pepels MJAE; Department of Internal Medicine, Elkerliek Hospital, Helmond, the Netherlands., van de Winkel L; Department of Internal Medicine, St Anna Hospital, Geldrop, the Netherlands., Peters NAJB; Department of Internal Medicine, Sint Jans Gasthuis Hospital, Weert, the Netherlands., Teeuwen-Dedroog NJA; Department of Medical Oncology, GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, PO BOX 5800, 6202 AZ, Maastricht, the Netherlands., Vriens IJH; Department of Medical Oncology, GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, PO BOX 5800, 6202 AZ, Maastricht, the Netherlands., Tjan-Heijnen VCG; Department of Medical Oncology, GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, PO BOX 5800, 6202 AZ, Maastricht, the Netherlands. vcg.tjan.heijnen@mumc.nl.

المصدر: Breast cancer research and treatment [Breast Cancer Res Treat] 2023 Apr; Vol. 198 (2), pp. 239-251. Date of Electronic Publication: 2023 Jan 12.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/drug therapy , Breast Neoplasms*/genetics , Breast Neoplasms*/metabolism, Humans ; Female ; Receptor, ErbB-2/genetics ; Receptor, ErbB-2/metabolism ; Trastuzumab/therapeutic use ; Disease-Free Survival ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use

المؤلفون: Meegdes M; Department of Medical Oncology, GROW School for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, the Netherlands., Geurts SME; Department of Medical Oncology, GROW School for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, the Netherlands., Erdkamp FLG; Department of Internal Medicine, Zuyderland Medical Center, Sittard-Geleen, the Netherlands., Dercksen MW; Department of Medical Oncology, Máxima Medical Center, Eindhoven, the Netherlands., Vriens BEPJ; Department of Internal Medicine, Catharina Hospital, Eindhoven, the Netherlands., Aaldering KNA; Department of Internal Medicine, Laurentius Hospital, Roermond, the Netherlands., Pepels MJAE; Department of Internal Medicine, Elkerliek Hospital, Helmond, the Netherlands., van de Winkel LMH; Department of Internal Medicine, St Anna Hospital, Geldrop, the Netherlands., Peters NAJB; Department of Internal Medicine, St. Jans Gasthuis, Weert, the Netherlands., Tol J; Department of Internal Medicine, Jeroen Bosch Ziekenhuis, Den Bosch, the Netherlands., Heijns JB; Department of Internal Medicine, Amphia Hospital Breda, the Netherlands., van de Wouw AJ; Department of Internal Medicine, Viecuri Medical Centre, Venlo, the Netherlands., de Fallois AJO; Department of Medical Oncology, GROW School for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, the Netherlands., van Kats MACE; Department of Medical Oncology, GROW School for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, the Netherlands., Tjan-Heijnen VCG; Department of Medical Oncology, GROW School for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, the Netherlands.

المصدر: The Lancet regional health. Europe [Lancet Reg Health Eur] 2023 Jan 06; Vol. 26, pp. 100573. Date of Electronic Publication: 2023 Jan 06 (Print Publication: 2023).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: [Oxford] Country of Publication: England NLM ID: 101777707 Publication Model: eCollection Cited Medium: Internet ISSN: 2666-7762 (Electronic) Linking ISSN: 26667762 NLM ISO Abbreviation: Lancet Reg Health Eur Subsets: PubMed not MEDLINE

المؤلفون: van den Berg K; Department of Medical Oncology, Catharina Hospital, Eindhoven, the Netherlands.; Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands., Schaap DP; Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands., Voogt ELK; Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands., Buffart TE; Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Medical Oncology, Amsterdam University Medical Centres, Amsterdam, the Netherlands., Verheul HMW; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, the Netherlands., de Groot JWB; Department of Medical Oncology, Isala Oncology Centre, Zwolle, the Netherlands., Verhoef C; Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Melenhorst J; Department of Surgery, Maastricht University Medical Centre, Maastricht, the Netherlands., Roodhart JML; Department of Medical Oncology, University Medical Centre Utrecht, Utrecht, the Netherlands., de Wilt JHW; Department of Surgery, Radboud University Medical Centre, Nijmegen, the Netherlands., van Westreenen HL; Department of Surgery, Isala, Zwolle, the Netherlands., Aalbers AGJ; Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., van 't Veer M; Department of Research and Education, Catharina Hospital, Eindhoven, the Netherlands., Marijnen CAM; Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Radiation Oncology, Leiden University Medical Center, Leiden, the Netherlands., Vincent J; Department of Medical Oncology, Elkerliek Hospital, Helmond, the Netherlands., Simkens LHJ; Department of Medical Oncology, Maxima Medical Centre, Veldhoven, the Netherlands., Peters NAJB; Department of Medical Oncology, St. Jans Hospital, Weert, the Netherlands., Berbée M; Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, the Netherlands., Werter IM; Department of Medical Oncology, Rijnstate Hospital, Arnhem, the Netherlands., Snaebjornsson P; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Peulen HMU; Department of Radiation Oncology, Catharina Hospital, Eindhoven, the Netherlands., van Lijnschoten IG; Department of Pathology, PAMM Laboratory for Pathology and Medical Microbiology, Eindhoven, the Netherlands., Roef MJ; Department of Nuclear Medicine, Catharina Hospital, Eindhoven, the Netherlands., Nieuwenhuijzen GAP; Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands., Bloemen JG; Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands., Willems JMWE; Department of Medical Oncology, Anna Hospital, Geldrop, the Netherlands., Creemers GJM; Department of Medical Oncology, Catharina Hospital, Eindhoven, the Netherlands., Nederend J; Department of Radiology, Catharina Hospital, Eindhoven, the Netherlands., Rutten HJT; Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands.; GROW School for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands., Burger JWA; Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands. pim.burger@catharinaziekenhuis.nl.

المصدر: BMC cancer [BMC Cancer] 2022 Sep 06; Vol. 22 (1), pp. 957. Date of Electronic Publication: 2022 Sep 06.

نوع المنشور: Clinical Trial Protocol; Journal Article

بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Neoplasms, Second Primary*/pathology , Rectal Neoplasms*/pathology, Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Camptothecin/analogs & derivatives ; Chemoradiotherapy/methods ; Clinical Trials, Phase II as Topic ; Fluorouracil/therapeutic use ; Humans ; Leucovorin ; Multicenter Studies as Topic ; Neoadjuvant Therapy/methods ; Neoplasm Staging ; Organoplatinum Compounds ; Quality of Life ; Treatment Outcome

SCR Protocol: FOLFOXIRI protocol

المؤلفون: Tullemans BME; Cardiovascular Research Institute Maastricht, Department of Biochemistry, Maastricht University, Maastricht, The Netherlands., Brouns SLN; Cardiovascular Research Institute Maastricht, Department of Biochemistry, Maastricht University, Maastricht, The Netherlands., Swieringa F; Cardiovascular Research Institute Maastricht, Department of Biochemistry, Maastricht University, Maastricht, The Netherlands.; Synapse Research Institute, Maastricht, The Netherlands., Sabrkhany S; Cardiovascular Research Institute Maastricht, Department of Physiology, Maastricht University, Maastricht, The Netherlands., van den Berkmortel FWPJ; Department of Medical Oncology, Zuyderland Medical Centre, Sittard-Geleen, The Netherlands., Peters NAJB; Department of Internal Medicine, Sint Jans Gasthuis, Weert, The Netherlands., de Bruijn P; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Centre, Rotterdam, The Netherlands., Koolen SLW; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Centre, Rotterdam, The Netherlands.; Department of Pharmacy, Erasmus University Medical Centre, Rotterdam, The Netherlands., Heemskerk JWM; Cardiovascular Research Institute Maastricht, Department of Biochemistry, Maastricht University, Maastricht, The Netherlands.; Synapse Research Institute, Maastricht, The Netherlands., Aarts MJB; Department of Medical Oncology, Maastricht University Medical Centre+, Maastricht, The Netherlands., Kuijpers MJE; Cardiovascular Research Institute Maastricht, Department of Biochemistry, Maastricht University, Maastricht, The Netherlands. Marijke.Kuijpers@maastrichtuniversity.nl.; Thrombosis Expertise Centre, Heart and Vascular Centre, Maastricht University Medical Centre, Maastricht, The Netherlands. Marijke.Kuijpers@maastrichtuniversity.nl.

المصدر: BMC cancer [BMC Cancer] 2022 Jun 13; Vol. 22 (1), pp. 653. Date of Electronic Publication: 2022 Jun 13.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents*/adverse effects , Carcinoma, Renal Cell*/pathology , Kidney Neoplasms*/pathology, Blood Platelets/pathology ; Humans ; Indoles/adverse effects ; Pyrroles/adverse effects ; Sunitinib/therapeutic use

المؤلفون: Meegdes M; Department of Internal Medicine, Division of Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands.; GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands., Ibragimova KIE; Department of Internal Medicine, Division of Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands.; GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands., Lobbezoo DJA; Department of Internal Medicine, Division of Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands., Vriens IJH; Department of Internal Medicine, Division of Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands.; GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands., Kooreman LFS; GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands.; Department of Pathology, Maastricht University Medical Centre, Maastricht, The Netherlands., Erdkamp FLG; Department of Internal Medicine, Zuyderland Medical Centre, Sittard-Geleen, The Netherlands., Dercksen MW; Department of Internal Medicine, Máxima Medical Centre, Veldhoven, The Netherlands., Vriens BEPJ; Department of Internal Medicine, Catharina Hospital, Eindhoven, The Netherlands., Aaldering KNA; Department of Internal Medicine, Laurentius Hospital, Roermond, The Netherlands., Pepels MJAE; Department of Internal Medicine, Elkerliek Hospital, Helmond, The Netherlands., van de Winkel LMH; Department of Internal Medicine, St Anna Hospital, Geldrop, The Netherlands., Tol J; Department of Internal Medicine, Jeroen Bosch Ziekenhuis, Den Bosch, The Netherlands., Heijns JB; Department of Internal Medicine, Amphia Hospital, Breda, The Netherlands., van de Wouw AJ; Department of Internal Medicine, Viecuri Medical Centre, Venlo, The Netherlands., Peters NAJB; Department of Internal Medicine, St. Jans Gasthuis, Weert, The Netherlands., Hochstenbach-Waelen A; Department of Internal Medicine, Division of Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands., Smidt ML; GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands.; Department of Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands., Geurts SME; Department of Internal Medicine, Division of Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands.; GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands., Tjan-Heijnen VCG; Department of Internal Medicine, Division of Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands. vcg.tjan.heijnen@mumc.nl.; GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands. vcg.tjan.heijnen@mumc.nl.

المصدر: Breast cancer research and treatment [Breast Cancer Res Treat] 2022 Apr; Vol. 192 (2), pp. 331-342. Date of Electronic Publication: 2022 Jan 13.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/epidemiology , Breast Neoplasms*/metabolism , Breast Neoplasms*/therapy, Biomarkers, Tumor/metabolism ; Female ; Hormones ; Humans ; Prognosis ; Receptor, ErbB-2/metabolism ; Receptors, Progesterone/genetics ; Receptors, Progesterone/metabolism ; Registries

المؤلفون: Smit KC; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, 3508 GA Utrecht, The Netherlands.; Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, 3584 CX Utrecht, The Netherlands., Derksen JWG; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, 3508 GA Utrecht, The Netherlands., Beets GLO; Department of Surgery, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.; GROW School for Oncology and Developmental Biology, Maastricht University, 6200 MD Maastricht, The Netherlands., Belt EJT; Department of Surgery, Albert Schweitzer Hospital, Albert Schweitzerplaats 25, 3318 AT Dordrecht, The Netherlands., Berbée M; Department of Radiotherapy, Maastro Clinic, 6202 NA Maastricht, The Netherlands., Coene PPLO; Department of Surgery, Maasstad Hospital, Maasstadweg 21, 3079 DZ Rotterdam, The Netherlands., van Cruijsen H; Department of Medical Oncology, Antonius Hospital, 8600 BA Sneek, The Netherlands., Davidis MA; Department of Medical Oncology, Rivas, Banneweg 57, 4204 AA Gorinchem, The Netherlands., Dekker JWT; Department of Surgery, Reinier de Graaf Hospital, Reinier de Graafweg 5, 2600 GA Delft, The Netherlands., van Dodewaard-de Jong JM; Department of Medical Oncology, Meander Medical Center, Maatweg 3, 3813 TZ Amersfoort, The Netherlands., Haringhuizen AW; Department of Medical Oncology, Ziekenhuis Gelderse Vallei, 6710 HN Ede, The Netherlands., Helgason HH; Department of Medical Oncology, Haaglanden Medical Center, 2501 CK Den Haag, The Netherlands., Hendriks MP; Department of Medical Oncology, Northwest Clinics, 1800 AM Alkmaar, The Netherlands., Hoekstra R; Department of Medical Oncology, Ziekenhuisgroep Twente, Zilvermeeuw 1, 7609 PP Hengelo, The Netherlands., de Hingh IHJT; Department of Surgery, Catharina Hospital, Michelangelolaan 2, 5623 EJ Eindhoven, The Netherlands., IJzermans JNM; Department of Surgery, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3000 AD Rotterdam, The Netherlands., Janssen JJB; Department of Medical Oncology, Canisius Wilhelmina Hospital, 6500 GS Nijmegen, The Netherlands., Konsten JLM; Department of Surgery, Viecuri Hospital, Tegelseweg 210, 5912 BL Venlo, The Netherlands., Los M; Department of Medical Oncology, St. Antonius Hospital, 3430 EM Nieuwegein, The Netherlands., Mekenkamp LJM; Department of Medical Oncology, Medisch Spectrum Twente, 7500 KA Enschede, The Netherlands., Nieboer P; Department of Medical Oncology, Wilhelmina Hospital, 9400 RA Assen, The Netherlands., Peeters KCMJ; Department of Surgery, Leiden University Medical Center, University of Leiden, Postzone K6-39 Albinusdreef 2, 2300 RC Leiden, The Netherlands., Peters NAJB; Department of Medical Oncology, Sint Jans Hospital, Vogelsbleek 5, 6001 BE Weert, The Netherlands., Pruijt HJFM; Department of Medical Oncology, Jeroen Bosch Hospital, 5200 ME Den Bosch, The Netherlands., Quarles van Ufford-Mannesse P; Department of Medical Oncology, Haga Hospital, Els Borst-Eilersplein 275, 2545 AA Den Haag, The Netherlands., Rietbroek RC; Department of Medical Oncology, Rode Kruis Hospital, Vondellaan 13, 1942 LE Beverwijk, The Netherlands., Schiphorst AHW; Department of Surgery, Diakonessenhuis Hospital, Bosboomstraat 1, 3582 KE Utrecht, The Netherlands., Schouten van der Velden A; Department of Surgery, St. Jansdal Hospital, Wethouder Jansenlaan 90, 3844 DG Harderwijk, The Netherlands., Schrauwen RWM; Department of Gastroenterology and Hepatology, Bernhoven Hospital, Nistelrodeseweg 10, 5406 PT Uden, The Netherlands., Sie MPS; Department of Medical Oncology, ZorgSaam Hospital, Wielingenlaan 2, 4535 PA Terneuzen, The Netherlands., Sommeijer DW; Department of Medical Oncology, Academisch Medisch Centrum, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.; Department of Medical Oncology, Flevo Hospital, Hospitaalweg 1, 1315 RA Almere, The Netherlands., Sonneveld DJA; Department of Surgery, Dijklander Hospital, Waterlandlaan 250, 1441 RN Purmerend, The Netherlands., Stockmann HBAC; Department of Surgery, Spaarne Hospital, 2000 AK Haarlem, The Netherlands., Tent M; Department of Medical Oncology, Treant Hospital, 7800 RA Emmen, The Netherlands., Terheggen F; Department of Medical Oncology, Bravis Hospital, Boerhaavelaan 25, 4708 AE Roosendaal, The Netherlands., Tjin-A-Ton MLR; Department of Medical Oncology, Rivierenland Hospital, 4000 HA Tiel, The Netherlands., Valkenburg-van Iersel L; Department of Medical Oncology, Maastricht University Medical Center, 6202 NA Maastricht, The Netherlands., van der Velden AMT; Department of Medical Oncology, Tergooi Hospital, Van Riebeeckweg 212, 1213 XZ Hilversum, The Netherlands., Vles WJ; Department of Surgery, Ikazia Hospital, Montessoriweg 1, 3083 AN Rotterdam, The Netherlands., van Voorthuizen T; Department of Medical Oncology, Rijnstate Hospital, Postus 9555, 6800 TA Arnhem, The Netherlands., Wegdam JA; Department of Surgery, Elkerliek Hospital, Wesselmanlaan 25, 5707 HA Helmond, The Netherlands., de Wilt JHW; Department of Surgery, Radboud University Medical Center, University of Nijmegen, 6500 HB Nijmegen, The Netherlands., Koopman M; Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, 3584 CX Utrecht, The Netherlands., May AM; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, 3508 GA Utrecht, The Netherlands., On Behalf Of The Plcrc Study Group

المصدر: Cancers [Cancers (Basel)] 2022 Feb 16; Vol. 14 (4). Date of Electronic Publication: 2022 Feb 16.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE

المؤلفون: Ibragimova KIE; Department of Medical Oncology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands.; GROW-School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands., Geurts SME; Department of Medical Oncology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands.; GROW-School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands., Croes S; Department of Medical Oncology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands., Erdkamp F; Department of Internal Medicine, Zuyderland Medical Center, Sittard-Geleen, The Netherlands., Heijns JB; Department of Medical Oncology, Amphia, Breda, The Netherlands., Tol J; Department of Medical Oncology, Jeroen Bosch Hospital, Den Bosch, The Netherlands., Vriens BEPJ; Department of Internal Medicine, Catharina Hospital, Eindhoven, The Netherlands., Aaldering KNA; Department of Internal Medicine, Laurentius Hospital, Roermond, The Netherlands., Dercksen MW; Department of Medical Oncology, Máxima Medical Center, Eindhoven, The Netherlands., Pepels MJAE; Department of Internal Medicine, Elkerliek Hospital, Helmond, The Netherlands., Peters NAJB; Department of Internal Medicine, Sint Jans Gasthuis, Weert, The Netherlands., van de Winkel L; Department of Internal Medicine, St Anna Hospital, Geldrop, The Netherlands., Tilli DJP; Department of Medical Oncology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands., Vriens IJH; Department of Medical Oncology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands.; GROW-School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands., de Boer M; Department of Medical Oncology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands.; GROW-School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands., Tjan-Heijnen VCG; Department of Medical Oncology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands. vcg.tjan.heijnen@mumc.nl.; GROW-School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands. vcg.tjan.heijnen@mumc.nl.

المصدر: Breast cancer research and treatment [Breast Cancer Res Treat] 2021 Jul; Vol. 188 (2), pp. 571-581. Date of Electronic Publication: 2021 Mar 20.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/drug therapy , Breast Neoplasms*/epidemiology, Antibodies, Monoclonal, Humanized ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Female ; Humans ; Netherlands/epidemiology ; Receptor, ErbB-2/genetics ; Registries ; Trastuzumab/therapeutic use